• If the 7.5% of all ACE inhibitor claims that were brand in 2008 were substituted with generic ACE inhibitors, the average price per claim would have been $17.64 rather than $24.03, representing a savings opportunity of $28.7 million (9%) for the Medicaid fee-for-service programs for combined ACE inhibitor-ARB spending. The total cost savings opportunity was as much as $142.3 million (46%), attainable with 100% generic ACE inhibitors and a 90% ratio of ACE inhibitors to total ARB and ACE inhibitors, associated with a reduction in the average price per claim from $44.52 to $24.07, excluding the effects of manufacturer rebate payments.
patients, left ventricular hypertrophy, reduction in the risk of stroke, and reduction in cardiovascular mortality following a myocardial infarction. 5 ARBs are also prescribed for patients who cannot tolerate an ACE inhibitor-induced cough. 8 On April 14, 1995, the FDA approved the first ARB, losartan (Cozaar), for clinical use in the United States. Cozaar dominated the ARB market briefly (Table 1 ). The most recent FDA approval of an ARB was olmesartan (Benicar) in April 2002. 6 Although none of the ARBs experienced generic entry during the study period, generic losartan and losartan/HCTZ have been available in the U.S. market since April 2010. 9 ARBs have not been shown to be more effective than ACE inhibitors in blood-pressure reduction or in slowing the progression of renal disease or slowing the progression to type-2 diabetes. 5 ARBs are associated with a lower incidence of cough, but the absolute rates of cough are often low including the headto-head trial of ramipiril (4.2%) versus telmisartan (1.1%) in ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial). 10 In 2009, 82.5 million prescriptions were dispensed for ARBs (which represent approximately 2% of all U.S. prescriptions), and the ARB class was ranked eleventh in prescription volume. 7 Cardiovascular mortality has been decreased by certain antihypertensive medications, including ACE inhibitors and ARBs. 11 Due to its high and rising prevalence, hypertension is an expensive disease. Moreover, the growing acceptance of ACE inhibitors and ARBs as first-line therapies in the treatment of hypertension coupled with a decline in cardiovascular disease mortality (leading to longer use of the antihypertensive medications) imply higher expenditures for drug treatment. A number of chronic disease conditions have propelled spending on prescription drugs, 12 and Medicaid and Medicare combined spending on outpatient prescription drugs was over $70 billion in 2008, much higher than 2 decades ago ( Figure 1 In response to rising prescription drug expenditures, state Medicaid programs have developed a variety of cost-containment strategies, including beneficiary cost sharing, preferred drug lists, formularies, requiring generic substitution, and prior authorization (PA) for certain types of medication. These strategies are not standardized, and each state has its own set of policies. 13 Fischer and Avorn (2003) estimated that there were potential cost savings for Medicaid of $450 million from greater overall use of generic drugs.
14 Due to the therapeutic interchangeability of ACE inhibitors and ARBs, coupled with the availability of inexpensive generic ACE inhibitors, many private payers require PA or step-therapy for ARBs. 15, 16 Hence, the present study has 2 objectives: (a) describe ACE inhibitor H ypertension is a major risk factor for the development of cardiovascular disease, including coronary artery disease, stroke, and heart failure. 1 According to the American Heart Association, there were 74.5 million people with hypertension (representing a 33.6% adult prevalence rate) and 5.8 million with heart failure in the United States (a 2.6% adult prevalence rate) in 2006. 2 In 2007, an estimated 17.5 million people in the United States were diagnosed with type 1 or type 2 diabetes, a disease that often coexists with hypertension. 3 Although thiazide-type diuretics are recommended as first-line therapy for uncomplicated hypertension, patients with stage 2 hypertension (systolic blood pressure equal to or greater than 160 mmHg) should be treated with a combination of 2 antihypertensive medications.
1 Angiotensin-converting enzyme (ACE) inhibitors are widely used in the treatment of hypertension. Their effect on the renin-angiotensin-aldosterone system, combined with improved ventricular remodeling, make ACE inhibitors an attractive option for heart failure patients, as well as for patients who have had a myocardial infarction. Multiple effects on the kidney, including a decrease in renovascular resistance, make ACE inhibitors appropriate also for decreasing the progression of nephropathy in patients with diabetes. 4 Labeled indications besides hypertension for the various ACE inhibitors include congestive heart failure; to improve survival following myocardial infarction; stable coronary artery disease; risk reduction for myocardial infarction, stroke, and death from cardiovascular causes; and left ventricular dysfunction after myocardial infarcation. 5 The first ACE inhibitor, captopril (Capoten), was approved by the U.S. Food and Drug Administration (FDA) in 1981 to treat hypertension and enjoyed market exclusivity for almost 5 years until the second ACE inhibitor, enalapril (Vasotec), was introduced at the end of 1985. Following enalapril, a number of other brand ACE inhibitors entered the market ( 17 The National Summary Files in the present study were compiled by aggregating state databases; the method is described in detail below. Since the data are collected as part of the Medicaid Rebate Program, they include fee-for-service but not managed Medicaid pharmacy claims. States differ in how their drug benefit programs are managed. Arizona, for example, is not included in the database because it is 100% managed care (i.e., Arizona Medicaid pharmacy claims are not eligible for federally negotiated manufacturer rebates). 18 The database appeared to contain coding errors in 2006 (all quarters) and 2007 Q3. During those 5 quarters, for some individual drugs including ACE inhibitors and ARBs, expenditures were incorrectly reported; hence, using the utilization data, which seemed to be correctly reported, we re-estimated expenditures for these 5 calendar quarters. For example, taking an average of per-unit (e.g., individual capsule or tablet) expenditure (i.e., pharmacy reimbursement) for quarters before and after the quarter in which a coding error occurred, we multiplied that average by the number of units. In this way, we came up with pharmacy reimbursement estimates that had better face validity. The general results from the present study were not affected by this small amount of data cleaning.
Each data record included the National Drug Code (NDC) number, drug name (trade or generic), year and quarter of Medicaid expenditure, number of pharmacy claims, number of units (e.g., individual capsules or tablets), and total pharmacy reimbursement amount, including drug cost and dispensing fee. The first 5 digits of the NDC number identified the drug manufacturer, while the remaining digits identify specific drug product by strength, dose formulation, and packaging. We searched the database for all ACE inhibitors and ARBs using both trade name and generic name (Table 1 ). For each of the drugs in Table 1 , and for the ACE inhibitor and ARB classes overall, quarterly claim counts and reimbursement amounts were calculated by summing data across individual NDCs for each of the drugs and then for each class of drugs, respectively. Data for all the generic versions of each drug were aggregated, and all the combination drugs (with diuretic or calcium channel blocker) were aggregated with their stand-alone counterparts (e.g., claims for lisinopril/HCTZ were combined with those for lisinopril). Market shares were calculated based on both number of prescriptions and Medicaid payments. 
ACE Inhibitors and ARBs by FDA Approval Date
Quarterly per-claim pharmacy reimbursement, as a proxy for drug price, was computed for all brand and generic ACE inhibitors and ARBs. Pharmacy reimbursements include the drug ingredient cost and dispensing fee but do not include manufacturer rebates (i.e., federally mandated rebates and supplemental state rebates have not been subtracted). All the data analyses were conducted using the SAS software package for Windows (Version 9.1.3, SAS Institute Inc., Cary, NC). Excel 2007 (Microsoft, Redmond, WA) was used to further develop the data. Table 2 (Table 2 ). There are several reasons for the 458% increase in spending on ACE inhibitors and ARBs. First, Medicaid enrollment has been increasing over time; in 1991, there were 28.3 million Medicaid beneficiaries, 21 and by 2005, there were 45.4 million Medicaid beneficiaries, a 60% increase in enrollment over this 14-year period. 22 In 2006, dual Medicaid-Medicare eligibles were transferred to Medicare Part D for their pharmacy benefit, resulting in a large drop in Medicaid spending for pharmaceuticals. However, the current economic recession that started in December 2007 brought significant job losses, loss of employer-offered health insurance, and a rise in the number of households requiring public assistance. 23 Second, the prevalence of cardiovascular disease and diabetes has been rising in the United States. The age-adjusted hypertension prevalence over the period 1988 to 1994 was 24.4% among U.S. adults, rising to 28.9% during the average per-claim prices can be determined for all of the individual ACE inhibitors and ARBs. All of the brand ACE inhibitors and ARBs have had rising prices over time. The average prices of generic captopril, enalapril, and lisinopril showed a steady decline after the entry of additional generic manufacturers. By 2008 Q4, the average price per claim was $9.93, $29.62, and $10.30 for captopril, enalapril, and lisinopril, respectively. The price of captopril decreased 85% from $55.30 in 1996 Q3 to $8.28 in 2005 Q4 as more and more captopril manufacturers entered the market and as the Medicaid programs were able to capture these savings through their reimbursement policies. Table 3 shows average prices for brand and generics for each of the ACE inhibitors and ARBs in 2008. Average reimbursement per claim was higher for several of the brand ACE inhibitors than for the ARBs, but the volumes were, of course, smaller (data not shown). 29 The proportion of ACE inhibitor or ARB patients who received an ARB was reduced from 31% to 18% in the 12 months following the intervention, producing $368,000 in annual savings or $0.03 per member per month (PMPM). An accompanying editorial pointed out that the cost savings were actually $0.06 PMPM if the step-therapy intervention had been followed for a full year, 30 closer to the cost savings of $0.11 PMPM reported by Gleason et al. for an ARB step-therapy intervention that was implemented in 2006. 31 Although some state Medicaid programs such as Massachusetts, Washington, Maine, and Indiana have a PA requirement, not all do. Fischer et al. (2007) , compared Medicaid expenditures for states with a PA requirement versus those without and found that step-therapy did indeed reduce ARB use and provided a method to significantly reduce Medicaid spending on antihypertensives. 32 
■■ Results

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid
Fee-For-Service Program from 1991 to 2008
■■ Limitations
First among the limitations is the potential invalidity of the Medicaid national database. When we summed all Medicaid fee-for-service claims in 2008 in the national database, we found that Medicaid had a total of $24.3 billion in expenditures on all outpatient prescription drugs. This number compares with the $21.0 billion National Health Expenditure figure upon which Figure 1 is based, but the $21 billion figure apparently includes spending on Medicaid beneficiaries in managed care as well as fee-for-service. Some of the higher cost in the national database of fee-for-service claims is explained by pharmacy reimbursement prior to subtraction of drug manufacturer rebates. However, the proportion of total Medicaid beneficiaries has risen significantly, from only 9.5% in 1991 to 40.1% in 1996 33 and 70.9% in 2008. 34 We did not determine the extent to which the national Medicaid fee-for-service database that we used includes managed Medicaid pharmacy benefits that are carved out of managed care.
Second, we discovered apparent errors in the national feefor-service database for 5 calendar quarters from the inception of Medicare Part D program in January 2006 through the first quarter of 2007, necessitating our recalculation of expenditures period from 1999 to 2004. 24 The age-adjusted (child plus adult) diabetes prevalence nearly doubled from 3.0% in 1991 to 5.7% in 2007. 25 Third, the mortality rate for cardiovascular disease has decreased over time; hence, individuals are now taking ACE inhibitors and ARBs, chronic heart medications, for longer periods. Since 1968, cardiovascular disease death rates have fallen in the United States, including a 4.0% average annual decline in the age-adjusted mortality rate from cardiovascular diseases from 1999 to 2006. 11 Finally, clinical guidelines and clinical trial results have encouraged increased prescribing of ACE inhibitors and ARBs. 1 Therefore, the increase in Medicaid spending on ACE inhibitors and ARBs is primarily attributable to increased utilization and not to price increases, although brand prices rose throughout the period. As shown in the last column of Table 2 , the average price per claim rose from $37.24 in 1991 to $41.02 in 2005, representing just a 10% increase.
The rise in utilization of these drugs is probably not due to combination therapy with ARBs and ACE inhibitors because combination therapy with these 2 drugs is not encouraged in the United States. 26 The Val-HeFT (Valsartan Heart Failure Trial) study showed beneficial effects on the combined endpoint of morbidity and mortality in patients who received an ARB in addition to ACE-inhibitor therapy, but subgroup analysis showed deleterious effects on morbidity and mortality when an ARB was given to patients receiving background therapy consisting of an ACE inhibitor plus a beta-blocker. 27 Moreover, the ONTARGET study suggested that although the combination therapy can cause further reduction of albuminuria relative to ACE inhibitor or ARB monotherapy, the combination therapy had an adverse effect on renal function. 10 In summarizing the results of the 4 trials devoted to ACE inhibitor and ARB combination therapy, McMurray (2008) concluded that the addition of an ARB to an ACE inhibitor had no benefit and increased the number of adverse events in patients with arterial disease. For patients with heart failure, however, the addition of an ARB might be beneficial. 28 Generally, in the United States, hypertensive patients take either an ACE inhibitor or ARB but not both.
The influences on spending already discussed are largely beyond the control of state Medicaid programs. However, there are 2 Medicaid policies that can have a major impact on spending in these drug classes. First, most state Medicaid programs either require or strongly encourage the use of generic drugs when they become available following patent expiration of their brand counterparts. 13 In 2008, 92.5% of Medicaid feefor-service ACE inhibitor pharmacy claims were for generics. However, since the average price per brand ACE inhibitor claim was $103.45 compared with an average generic price per claim of $17.64, the Medicaid state programs together could have saved $28.7 million (for 335,925 brand ACE inhibitor claims) to match the claims volume for ARBs and ACE inhibitors. However, these data manipulations did not affect our primary cost savings calculations, which were based on claims data in 2008.
A third limitation of this research is the inability to consider the effects of drug manufacturer rebates in reducing the net cost to the Medicaid programs. The Medicaid Drug Rebate Program, established by the Omnibus Budget Reconciliation Act of 1990, requires a drug manufacturer to enter into and have in effect a national rebate agreement with the secretary of the Department of Health and Human Services in order for states to receive federal funding for outpatient drugs dispensed to Medicaid patients. Rebate percentages are based on average manufacturer prices, and the percentage is higher for innovator drugs than for noninnovator (generic) drugs. 35 In addition, a number of states have been collecting state-only supplemental rebates in conjunction with a preferred drug list. 13 Therefore, the claims data that we used in the present study overstate the actual net drug acquisition cost to the Medicaid programs by ignoring rebates and do not include the managed Medicaid pharmacy claims that are not part of the federally administered Medicaid Drug Rebate Program.
■■ Conclusions
In 2008, state Medicaid programs spent $309.8 million on ACE inhibitors and ARBs. Although many factors explaining this expense by affecting utilization (e.g., prevalence of hypertension, heart disease, and diabetes) are beyond the control of program administrators, cost savings can be obtained through a higher percentage of generic drug prescriptions and a higher percentage of ACE inhibitors in the total of ACE inhibitor and ARB utilization. In 2008, Medicaid could have saved up to $28.7 million (9%) through 100% utilization of generic ACE inhibitors and up to $142.3 million from 90% utilization of ACE inhibitors in the combined class of ARBs and ACE inhibitors.
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